Novo Nordisk (NVO) stock jumped early Wednesday after the weight-loss drugs leader reported adjusted earnings of 88 cents per share on $11.92 billion in fourth-quarter sales.

Analysts polled by FactSet expected Novo to earn 83 cents a share on $11.14 billion in sales.

In the year-earlier period, Novo earned 72 cents a share and had $9.6 billion in sales.

Wegovy, the company's obesity drug, generated $2.77 billion in sales, just shy of expectations for $2.78 billion. Ozempic, the diabetes treatment that uses the same semaglutide active ingredient, brought in $4.77 billion in sales. That beat forecasts for $4.59 billion.

For the year, Novo Nordisk guided to 16% to 24% sales growth, excluding the impact of exchange rates. However, Novo noted the outlook includes expectations for "continued periodic supply constraints and related drug shortage notifications across a number of products and geographies." The Street projected earnings of $3.82 per share and $48.18 billion in sales.

In premarket trades on the stock market today, Novo Nordisk stock jumped 4% to 85.91.

More to follow.

YOU MAY ALSO LIKE:

Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares

RFK Jr. Clears A Key Hurdle To Head Up HHS. Why His Nomination Is A Biotech Black Box.

Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists

Join IBD Live For Stock Ideas Each Morning Before The Open

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks